Biotech Insider Buying: Synageva BioPharma Corp. (NASDAQ:GEVA), VIVUS Inc. (NASDAQ:VVUS), TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Synageva BioPharma Corp. (NASDAQ:GEVA), Director Julian Baker acquired 1,000,000 shares of Synageva BioPharma Corp. (NASDAQ:GEVA) stock in a transaction that occurred on Wednesday, January 7th. The shares were purchased at an average cost of $94.19 per share, for a total transaction of $94,190,000.00. On Monday shares of Synageva BioPharma Corp. (NASDAQ:GEVA) closed at $110.58. Company’s sales growth for last 5 years was -7.30%.

VIVUS Inc. (NASDAQ:VVUS) major shareholder North Tide Capital, Llc bought 500,000 shares of the stock on the open market in a transaction that occurred on Thursday, January 8th. The shares were purchased at an average cost of $3.12 per share, with a total value of $1,560,000.00. VIVUS Inc. (NASDAQ:VVUS) in last trading activity advanced 2.80% to close at $3.30. Company weekly performance is 8.55% while its quarterly performance stands at 3.13%. VIVUS Inc. (NASDAQ:VVUS) is -66.33% away from its 52 week high.

TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) CEO J Kevin Buchi purchased 5,000 shares of the stock on the open market in a transaction that occurred on Wednesday, January 7th. The stock was purchased at an average cost of $5.04 per share, for a total transaction of $25,200.00.On last trading day TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) advanced 11.93% to close at $6.10. Its volatility for the week is 10.29% while volatility for the month is 9.67%. TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) monthly performance is -1.61%.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND), The Securities and Exchange Commission has divulged in a Form 4 filing that the VP, Gen. Counsel & Secretary of Ligand Pharmaceuticals Inc, Berkman Charles S had purchased shares worth of $5,699 in a transaction dated on December 31, 2014. A total of 126 shares were purchased at a price of $45.23 per share. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has 2.20% insider ownership while its institutional ownership stands at 94.10%. In last trading activity company’s stock closed at $51.54.

Leave a Reply

Your email address will not be published. Required fields are marked *

*